SCC062
HMC-1.2 Human Mast Cell Line
Human
Synonym(s):
HMC-1 cell line
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41106514
eCl@ss:
32011203
NACRES:
NA.81
Recommended Products
product name
HMC-1.2 Human Mast Cell Line, HMC-1.2 human mast cell line is a variant subline of the HMC-1 cell line and possesses both the V560G and D816V KIT mutations.
biological source
human
Quality Level
technique(s)
cell culture | mammalian: suitable
shipped in
dry ice
Related Categories
General description
HMC-1 cell line was established from a patient with mast cell leukemia. HMC-1 cells are widely used in studies of human mast cell function because they exhibit many key characteristics of tissue mast cells, such as expression of histamine, tryptase, heparin and similar cell surface antigen-profile (1,2). Receptor tyrosine kinase KIT is expressed on mast cells and plays an important role in the proliferation, function and survival of mast cells. Activating mutations in KIT have been linked to dysregulated growth of mast cells and are associated with mast cell tumors and systemic mastocytosis. Two activating point mutations in KIT have been reported in the HMC-1 cell line (3). Both mutations convert the receptor to a constitutively tyrosine phosphorylated and active state, leading to growth factor-independent proliferation.
1. Nilsson, G, et al. (1994) Phenotypic Characterization of the Human Mast-Cell Line HMC-1. Scand. J. Immunol 39: 489-498.
2. Sundstrom, M, et al. (2003) Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 108: 89-97.
3. Furitsu, T, et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92(4): 1736-4.
1. Nilsson, G, et al. (1994) Phenotypic Characterization of the Human Mast-Cell Line HMC-1. Scand. J. Immunol 39: 489-498.
2. Sundstrom, M, et al. (2003) Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 108: 89-97.
3. Furitsu, T, et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92(4): 1736-4.
HMC-1.1 (HMC-1(560)) and HMC-1.2 (HMC-1(560,816)) are two variant sublines of the HMC-1 cell line (2). HMC-1.1 possess the V560G mutation, but not the D816V mutation. HMC-1.2 possess both the V560G and D816V mutations and exhibits a higher proliferative rate than HMC-1.1. It has been suggested that the higher proliferative potential of HMC-1.2 may be attributed to the D816V mutation.
Cell Line Description
Cancer Cells
Application
Research Category
Inflammation & Immunology
Cancer
Inflammation & Immunology
Cancer
This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.
Quality
• Each vial contains ≥ 1X106 viable cells.
• Cells are tested by PCR and are negative for HPV-16, HPV-18, Hepatitis A, B, C and HIV-1 & 2 viruses.
• Cells are negative for mycoplasma contamination.
• Each lot of cells are genotyped by STR analysis to verify the unique identity of the cell line.
• Cells are tested by PCR and are negative for HPV-16, HPV-18, Hepatitis A, B, C and HIV-1 & 2 viruses.
• Cells are negative for mycoplasma contamination.
• Each lot of cells are genotyped by STR analysis to verify the unique identity of the cell line.
Storage and Stability
Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
Other Notes
Concentration: Please refer to lot specific datasheet.
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yunju Nam et al.
Cancers, 15(1) (2023-01-09)
c-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4-b]pyridine derivatives and performed SAR studies. We observed that, among these substances, 6r
Rubí Vega-Hernández et al.
Microorganisms, 9(11) (2021-11-28)
Urinary tract infections (UTIs) are a public health problem in Mexico, and uropathogenic Escherichia coli (UPEC) is one of the main etiological agents. Flagella, type I fimbriae, and curli promote the ability of these bacteria to successfully colonize its host.
Poi Yi Aw Yong et al.
BMC complementary medicine and therapies, 23(1), 307-307 (2023-09-05)
Allergy is an inflammatory disorder affecting around 20% of the global population. The adverse effects of current conventional treatments give rise to the increased popularity of using natural food products as complementary and alternative medicine against allergic diseases. Stingless bee
Anu Gupta et al.
Molecular cancer therapeutics, 20(7), 1234-1245 (2021-05-06)
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for metastatic or unresectable KIT-driven GIST. Treatment of patients with GIST
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service